Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov 1;319(5):F780-F781.
doi: 10.1152/ajprenal.00518.2020. Epub 2020 Oct 5.

SGLT2 inhibitors: diabetic kidney disease and beyond

Alexander Staruschenko  1   2 , Vivek Bhalla  3 , Janani Rangaswami  4   5
Affiliations
Editorial

SGLT2 inhibitors: diabetic kidney disease and beyond

Alexander Staruschenko et al. Am J Physiol Renal Physiol. .
No abstract available

Keywords: Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial; Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease trial; kidney in cardiovascular disease; sodium-glucose cotransporter-2; sodium-glucose cotransporter-2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest, financial or otherwise, are declared by the author(s).

Comment on

References

    1. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators . Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol 50: 333–344, 2019. doi:10.1159/000503713. - DOI - PMC - PubMed
    1. Braden GL, Chapman A, Ellison DH, Gadegbeku CA, Gurley SB, Igarashi P, Kelepouris E, Moxey-Mims MM, Okusa MD, Plumb TJ, Quaggin SE, Salant DJ, Segal MS, Shankland SJ, Somlo S. Advancing nephrology: division leaders advise ASN. Clin J Am Soc Nephrol. In press. doi:10.2215/CJN.01550220. - DOI - PMC - PubMed
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde A-M, Wheeler DC; DAPA-CKD Trial Committees and Investigators . Dapagliflozin in patients with chronic kidney disease. N Engl J Med. In press. doi:10.1056/NEJMoa2024816. - DOI - PubMed
    1. León Jiménez D, Cherney DZI, Bjornstad P, Castilla-Guerra L, Miramontes González JP. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am J Physiol Renal Physiol 315: F1406–F1415, 2018. doi:10.1152/ajprenal.00384.2017. - DOI - PMC - PubMed
    1. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017. doi:10.1056/NEJMoa1611925. - DOI - PubMed

Publication types

MeSH terms

Substances